top of page
News and Milestones

February 27, 2024

CHO Plus Strengthens and Expands Leadership Team with Key Appointment

Joseph Tarnowski joins CHO Plus as Chief Technology and Business Officer

April 23 – 28, 2023

Cell Culture Engineering XVIII

CHO Plus presented three posters describing our cell engineering platform, our latest mAb production results (9.5 g/l; 117 pg/cell/day; 60-generation stability), and our latest AAV production results (9-fold higher productivity; 2-fold higher capsid percent-full)
(click here to see our poster presentations)

February 27 – March 2, 2023

BPI West

New and updated results will be presented for high-productivity CHO cells for mAb production, including stability; also for high-productivity HEK cells for AAV production
Oral presentation on March 2: Novel Cell Engineering Platform for Creating High-Productivity Cells for Therapeutic Protein Production, and for Other Purposes.

August 15 - 18, 2022

BioProcessing Summit

CHO Plus announces 9.5 g/l human mAb productivity in CHO cell cultures 

Poster Presentation: New Cell Engineering Method for Increasing Recombinant Therapeutic Antibody Productivity Up To 10-Fold in Batch CHO Cultures 

June 26 - 29, 2022

ESACT

Poster Presentation: New Cell Engineering Method for Increasing Recombinant Therapeutic Antibody Productivity Up To 10-Fold in Batch CHO Cultures

August 24, 2021

CHO Plus Announces Acceptance into BLUE KNIGHT™

CHO Plus’s participation in this joint initiative is another step toward commercializing its patented cell engineering technology

 

December 21, 2020

CHO Plus moves to Johnson & Johnson Innovation - JLABS @ South San Francisco

December 1, 2020

CHO Plus Announces Research Collaboration Agreement with Janssen

Collaboration will move CHO Plus closer to commercializing its patented cell engineering technology

June 25, 2019

Key US patent issued to CHO Plus.  Patent No. US 10,329,594:
Cell Lines for High Level Production of Protein-Based Pharmaceuticals

June 1, 2019

James Panek joins CHO Plus as Chief Operating Officer.  Jim is an experienced pharma executive who held such positions as Senior VP, Product Operations at Genentech.

March 26, 2016

Presented company to investors at EPPICon 2016, Burlingame, CA 

First place in Speed Pitch session

 

March 2, 2016

Presented company to investors at Venture Summit - West, Mountain View, CA

 

October 2015

Patent application filed: Identifying high transcription areas in cell genomes to enhance production of biopharmaceuticals

 

September 2015

Patent application filed: Cell Lines for High Level Production of Protein-based Pharmaceuticals

 

June 2015

CHO Plus genetically engineered CHO cells shown to have 4.5-fold higher productivity than parent CHO-K1 cell line

 

September 2014

Research operations commence at qb3@953 in San Francisco

 

March 2014

CHO Plus incorporates in Delaware

bottom of page